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Abstract 
Background: While single nucleotide polymorphisms (SNP) in genes involved in DNA repair or 
drug metabolism have been shown to influence survival of metastatic colon cancer patients treated 
with FOLFOX, data on adjuvant setting are scarce.  
Methods: This study evaluated the correlation between disease-free survival (DFS) of 210 un-
selected stage III colon cancer patients receiving FOLFOX chemotherapy, and ERCC1-118 
(rs11615, c.354T>C), XRCC1-399 (rs25487, c.1196G>A) and GSTP1-105 (rs1695, c.313A>G) 
polymorphisms. SNP were determined on tumor DNA using a PCR-based RFLP technique.  
Results: In univariate analysis, a trend towards longer DFS was observed for ERCC1 (C/T + T/T) 
versus (C/C) (HR=2.29; p=0.06), and XRCC1 (A/A) versus (G/G + G/A) (HR=1.61; p=0.16), but 
not for GSTP1 genotypes; a statistically significant p value was obtained when combining ERCC1 and 
XRCC1 favorable genotypes (0 versus ≥ 1 favorable genotypes, HR=2.42; p=0.02). After adjust-
ment on tumor stage, lymph node ratio and differentiation grade, multivariate analysis showed that 
combining ERCC1 and XRCC1 genotypes gave a p value slightly above the threshold for statistical 
significance (HR=2.03; p=0.06), which was lower than for tumor stage, lymph node ratio or dif-








Conclusion: The association of ERCC1 and XRCC1 polymorphisms may influence the prognosis of 
stage III colon cancer patients treated with FOLFOX adjuvant chemotherapy. Yet, these findings 
need to be confirmed in independent prospective studies. 
Key words: colon cancer, adjuvant FOLFOX, polymorphism, ERCC1, XRCC1, GSTP1. 
Introduction 
Oxaliplatin is a platinum-based chemotherapeu-
tic agent that carries 1,2-diamino-cyclohexane ring. 
This chemotherapeutic agent has shown in vitro and in 
vivo antitumor activities in colorectal cancer (CRC) (1). 
The administration of oxaliplatin in combination with 
5-fluorouracil (5FU) (FOLFOX regimen) significantly 
improved progression-free survival and response rate 
for patients with metastatic CRC (2). More recently, 
the addition of oxaliplatin to 5FU was demonstrated 
to improve the adjuvant treatment of stage III colon 
cancer by reducing the risk of recurrence and in-
creasing overall survival (3, 4). However, oxaliplatin 
failed to eradicate micrometastatic disease in ap-
proximately one third of stage III colon cancer pa-
tients. Oxaliplatin exerts its action by forming 
DNA-platinum mono-adducts, primarily with gua-
nines, which inhibits DNA replication and transcrip-
tion and induces apoptosis (1). Unlike cisplatin, oxal-
iplatin-induced adducts are apparently not recog-
nized by the mismatch repair (MMR) system, but are 
predominantly repaired by the nucleotide excision 
repair (NER) and base excision repair (BER) pathways 
(5, 6). An enhanced DNA repair efficiency or a de-
creased accumulation of the cytotoxic agent may con-
tribute to resistance to platinum drugs.  
Several studies reported that single nucleotide 
polymorphisms (SNP) in genes involved in DNA re-
pair, as Excision Repair Cross-Complementing group 1 
(ERCC1) (7) and X-Ray Repair Cross-Complementing 
group 1 (XRCC1) (8, 9), or involved in drug metabo-
lism, as glutathione S-transferases P1 (GSTP1) (10-12), 
may predict the clinical outcome for patients receiving 
oxaliplatin-based chemotherapy for metastatic CRC 
treatment. ERCC1 forms a heterodimeric complex 
with Xeroderma Pigmentosum Group F, that has an 
important role in the incision process of NER (13). 
XRCC1 interacts with many proteins involved in sin-
gle-strand break repair and in BER, participating in 
some of the rate-limiting reactions (14). Finally, glu-
tathione S-transferases are implicated in drug detoxi-
fication through the conjugation of glutathione to 
electrophilic xenobiotics. The GSTP1 isoenzyme that 
participates in the detoxification of platinum drugs is 
highly expressed in human CRC tissues and could 
possibly influence resistance to platinum-based 
chemotherapy (15). To our knowledge, the impact of 
polymorphisms in these genes on the survival of pa-
tients treated with oxaliplatin-based adjuvant chem-
otherapy has been scarcely explored yet. Thus, in the 
current study, we have examined the influence of 
ERCC1 (Asn118Asn), XRCC1 (Arg399Gln) and GSTP1 
(Ile105Val) polymorphisms, separately or in combi-
nation, on disease-free survival (DFS) of patients with 




We retrospectively collected data of all consecu-
tive patients treated with FOLFOX adjuvant chemo-
therapy after surgical resection of a stage III colon 
cancer between 06/2003 and 12/2007 in 3 University 
centers (Ambroise Paré, Georges Pompidou, and 
Saint-Antoine hospitals) and 1 private hospital (Mu-
tualiste Montsouris Institute). Patients were eligible 
for this retrospective multicenter study if they met the 
following criteria: older than 18 years, histologically 
proven colon cancer, at least 1 pathologically involved 
lymph node, R0 resection, available tumor specimen 
in the pathology departments, adjuvant FOLFOX 
chemotherapy starting within 8 weeks after surgery 
and no history of sensitive peripheral neuropathy. 
Fourteen stage III colon cancer patients enrolled in the 
MOSAIC trial with available tumor and treated in 
these centers with FOLFOX between 11/1998 and 
10/2000 were also included. Patients with rectal can-
cer or treated with abdominopelvic radiotherapy have 
been excluded. This retrospective pharmacogenetic 
study has been approved by the ethics committee of 
the Pitié-Salpétrière Hospital (Paris, France).  
Treatment and follow-up 
The chemotherapy cycle consisted of a 2-hour 
infusion of 85 mg of oxaliplatin per square meter on 
day 1, in addition to the standard LV5FU2 regimen 
(FOLFOX4) or the simplified LV5FU2 regimen (mod-
ified FOLFOX6) (3, 16). Patients were scheduled to 
receive one cycle of chemotherapy every two weeks 
for 6 months. After treatment, a control visit was 
performed every 3 to 6 months for 3 years, then every 
6 months for 2 years, then annually, to assess potential 
disease recurrence. Physical examination, serum car-
cinoembryonic antigen assay, and abdominal plus 
thoracic imaging were performed at each visit.  




DNA extraction and genotyping 
Genomic DNA was extracted from 20-µm-thick 
tissue sections of frozen tumors (111 patients) or from 
7-µm tissue sections of paraffin-embedded tumors 
when frozen samples were not available (99 patients). 
Areas of tumor tissues were previously delineated by 
microscopic examination of a reference slide stained 
with haematoxylin and eosin. Extraction was done 
using the NucleoSpin Tissue Kit (Macherey-Nagel) for 
frozen samples and NucleoSpin DNA FFPE Kit (Ma-
cherey-Nagel) or KAPA Express DNA Extraction Kit 
(Kapa Biosystems) for paraffin-embedded tissues, 
according the manufacturers' instructions.  
SNP genotyping analyses were done on 
amplified tumor DNA followed by digestion with the 
corresponding restriction enzyme: BsrD1 (New 
England Biolabs) for ERCC1 (rs11615, c.354T>C, 
p.Asn118Asn) (17), Hpall (Fermentas) for XRCC1 
(rs25487, c.1196G>A, p.Arg399Gln) and Alw26I 
(Fermentas) for GSTP1 (rs1695, c.313A>G, 
p.Ile105Val) polymorphisms. For ERCC1-118, a 239 bp 
fragment was amplified using 5’-GTGCGAGGAGGC
AGGAGGTGTGGG-3’ and 5’-GAGCTCACCTGAGG
AACAGG-3’, as primers. BsrD1 cleaves the ERCC1 T 
allele into two fragments of 155 and 84 bp. For 
XRCC1-399, a 242 bp was amplified using 
5’-CCCCAAGTACAGCCAGGTCC-3’ and 5’–CCGCT
CCTCTCAGTAGTCTG-3’ as primers. The XRCC1 G 
allele is cleaved by HpaII into two fragments of 149 
and 93 bp. For GSTP1-105, a 176 bp was amplified 
using 5’-ACCCCAGGGCTCTATGGGAAG-3’ and 
5’-TGAGGGCACAAGAAGCCCCT-3’ as primers. 
Alw26I cleaves the G allele into two fragments of 89 
and 87 bp. After digestion, the PCR fragments were 
electrophoresed in a 2% agarose gel in the presence of 
GelRed™ (1/10000, Biotium Inc) and visualized using 
a G: BOX gel imaging system (Syngene, Ozyme). 
Statistical analysis 
Differences in distributions between the clini-
co-pathological variables listed in Table 1 were as-
sessed with the Chi2 or the Fisher’s exact test, as ap-
propriate. The cut-off value of lymph node ratio 
(LNR) between metastatic and examined lymph 
nodes corresponded to the median. The number of 
FOLFOX cycles according to the 3 possible genotypes 
of each gene was compared using a non-parametric 
Kruskal-Wallis test.  
Table 1. Clinicopathological characteristics of patients with stage III colon cancer according to ERCC1-118, XRCC1-399 and GSTP1-105 polymorphisms. 
Characteristics All  
patients 
ERCC1-118 (rs11615)  XRCC1-399 (rs25487) GSTP1-105 (rs1695) 




No. of patients (%) p No. of patients (%) p No. of patients (%) p 
C/C C/T T/T  G/G G/A A/A  A/A A/G G/G  
49 88 65  94 80 33  97 92 20  
Age              
Median 65.9 64.3 64.4 66.3  65.9 64.9 64.5  66.8 63.4 61.7  
Range 30.5 - 82.8 30.5 - 82.8 31.1 - 81.0 37.8 - 82.8  30.8 - 82.1 37.8 - 82.8 30.5 - 77.4  30.8 - 81.0 30.5 - 82.8 40.9 - 81.0  
< 65 yr 101 (48.1) 26 (53.1) 44 (50.0) 29 (44.6) 0.65 44 (46.8) 40 (50.0) 16 (48.5) 0.92 39 (40.2) 50 (54.3) 12 (60.0) 0.08 
Sex              
Female 99 (47.1) 23 (46.9) 40 (45.4) 31 (47.7) 0.96 39 (41.5) 39 (48.8) 19 (57.6) 0.26 42 (43.3) 48 (52.2) 9 (45.0) 0.46 
Male  111 (52.9) 26 (53.1) 48 (54.6) 34 (52.3) 55 (58.5) 41 (51.2) 14 (42.4) 55 (56.7) 44 (47.8) 11 (55.0) 
Tumor location              
Proximal 67 (31.9) 16 (32.7) 28 (31.8) 22 (33.8) 0.97 31 (33.0) 27 (33.8) 9 (27.3) 0.79 27 (27.8) 34 (37.0) 6 (30.0) 0.40 
Distal 143 (68.1) 33 (67.3) 60 (68.2) 43 (66.2) 63 (67.0) 53 (66.2) 24 (72.7) 70 (72.2) 58 (63.0) 14 (70.0) 
Differentiation grade              
Well / moderate 182 (86.7) 45 (91.8) 76 (86.4) 55 (84.6) 0.50 82 (87.2) 69 (86.2) 29 (87.9) 1.00 82 (84.5) 81 (88.0) 18 (90.0) 0.76 
Poor 28 (13.3) 4 (8.2) 12 (13.6) 10 (15.4) 12 (12.8) 11 (13.8) 4 (12.1) 15 (15.5) 11 (12.0) 2 (10.0) 
Bowel perforation / obstruction 16 (7.6) 6 (12.2) 6 (6.8) 2 (3.1) 0.16 9 (9.6) 5 (6.3) 2 (6.1) 0.73 8 (8.2) 7 (7.6) 0 (0.0) 0.58 
Stage              
III A (T1-T2, N1) 23 (11.0) 9 (18.4) 6 (6.8) 7 (10.8) 0.07 14 (14.9) 5 (6.3) 4 (12.1) 0.37 9 (9.3) 11 (12.0) 3 (15.0) 0.90 
III B (T3-T4, N1) 108 (51.4) 29 (59.2) 43 (48.9) 33 (50.8) 46 (48.9) 46 (57.5) 15 (45.5) 51 (52.6) 47 (51.0) 9 (45.0) 
III C (Tx, N2) 79 (37.6) 11 (22.4) 39 (44.3) 25 (38.4) 34 (36.2) 29 (36.2) 14 (42.4) 37 (38.1) 34 (37.0) 8 (40.0) 
Lymph node ratio              
< 0.100 102 (48.6) 30 (61.2) 43 (48.9) 29 (44.6) 0.20 44 (46.8) 43 (53.8) 15 (45.5) 0.59 50 (51.5) 41 (44.6) 11 (55.0) 0.53 
≥ 0.100 108 (51.4) 19 (38.8) 45 (51.1) 36 (55.4) 50 (53.2) 37 (46.2) 18 (54.5) 47 (48.5) 51 (55.4) 9 (45.0) 
MMR status              
dMMR 17 (8.1) 6 (12.2) 3 (3.4) 7 (10.8) 0.09 9 (9.6) 7 (8.8) 1 (3.0) 0.59 5 (5.2) 11 (12.0) 1 (5.0) 0.21 
pMMR 193 (91.9) 43 (87.8) 85 (96.6) 58 (89.2) 85 (90.4) 73 (91.2) 32 (97.0) 92 (94.8) 81 (88.0) 19 (95.0) 
No. of FOLFOX cycles              
Median 11 11 10 11 0.90 12 10 11 0.09 11 10 12 0.40 
Abbreviations: ERCC1, Excision repair cross-complementing group 1; XRCC1, X-ray repair cross-complementing group 1; GSTP1, glutathione-S-transferase P1; dMMR, defective DNA 
Mismatch Repair; pMMR, proficient DNA Mismatch Repair. The cut-off value of LNR between metastatic and examined lymph nodes correponded to the median. The p values have been 
determined using the Chi² test or Fisher's exact test, as appropriate. The number of FOLFOX cycles according to the 3 possible genotypes of each gene was compared using a 
non-parametric Kruskal-Wallis test. 
Unknown data: ERCC1 polymorphism for eight patients; XRCC1 polymorphism for three patients; GSTP1 polymorphism for one patient. 
 




The primary endpoint was DFS, defined as the 
time between the date of surgery and the first event 
(local or distant disease recurrence or death from any 
cause, whichever occurred first). Patients who were 
alive and relapse-free at the last contact were censored 
at the last follow-up date.  
Univariate and multivariate Cox proportional 
hazard regression models were used to estimate the 
hazard ratio (HR) and 95% confidence interval (CI). 
The following variables were examined in univariate 
analyses for their relation with DFS: age, sex, tumor 
location, differentiation grade, bowel perforation or 
obstruction, tumor stage, LNR, MMR status and 
polymorphisms in ERCC1-118, XRCC1-399 and 
GSTP1-105, alone or in combination for ERCC1 and 
XRCC1. Yet, the ERCC1 and XRCC1 combining vari-
able was included in the multivariate model in order 
to take into account the significant interaction 
(p < 0.05) found between ERCC1-118 and XRCC1-399 
polymorphisms. MMR status was defined by im-
munohistochemistry as previously described (18). All 
variables potentially associated with DFS and having 
a univariate p value ≤ 0.10 were included in multi-
variate analyses. The multivariate Cox model was 
constructed according to the "one variable for 10 
events" rule. The discriminatory capacity was tested 
using the Harrell’s concordance index. Harrell’s C 
statistic was used to estimate the proportion of correct 
predictions. Harrell’s C index ranges from 0.5 (no 
discrimination) to 1 (perfect discrimination). P values 
< 0.05 were considered as statistically significant. All 
analyses were performed using Stata V11 software 
(StataCorp LP, College Station, TX). The cutoff date 
for this analysis was December 2010. 
Results 
Patient characteristics 
A total of 210 patients were included in this 
study. The median number of FOLFOX cycles re-
ceived was 10 for the whole population and there was 
no statistically significant difference in the median 
number of cycles received by patients according to the 
genotypes of any of the 3 genes analyzed (Table 1). 
The median follow-up was 47.3 months (95% CI, 
42.8 – 48.7). At the end of follow-up, 48 patients 
(22.8%) had relapsed or died in the whole study pop-
ulation. The 3-year DFS rate was 78.3% (95% CI, 71.8 – 
83.4). The clinicopathological characteristics of pa-
tients according to ERCC1-118, XRCC1-399 and 
GSTP1-105 polymorphisms are summarized in Table 
1. The ERCC1-118, XRCC1-399 and GSPTP1-105 gen-
otypes were successfully determined for 202, 207 and 
209 patients, respectively. There was no significant 
correlation between clinicopathological characteristics 
and ERCC1-118, XRCC1-399 or GSTP1-105 polymor-
phisms (Table 1).  
Association between the ERCC1, XRCC1 and 
GSTP1 polymorphisms and DFS 
ERCC1-118. Among the 202 patients whose 
ERCC1 genotype was defined, 45 (22.3%) had re-
lapsed or died (6 with the C/C genotype, 24 with 
C/T, and 15 with T/T). The 3-year DFS rate was 88.9% 
(95% CI, 75.3 – 95.2), 73.8% (95% CI, 63.0 – 81.9), and 
78.8% (95% CI, 66.3 – 87.1) in patients with homozy-
gous C/C, heterozygous C/T and homozygous T/T 
genotypes, respectively (log-rank test, p=0.12) 
(Fig.1A). 
XRCC1-399. Among the 207 patients whose 
XRCC1 genotype was defined, 48 (23.2%) had re-
lapsed or died (22 with the G/G genotype, 15 with 
G/A, and 11 with A/A). The 3-year DFS rate was 
78.9% (95% CI, 68.9 – 86.0), 82.2% (95% CI, 71.3 – 89.3), 
and 66.0% (95% CI, 47.0 – 79.6) in patients with G/G, 
G/A and A/A genotypes, respectively (log-rank test, 
p=0.31) (Fig. 1B). 
 
 
Figure 1. DFS of stage III colon cancer patients receiving FOLFOX according to ERCC1, XRCC1 and GSTP1 polymorphisms. Dis-
ease-free survival curves of stage III colon cancer patients receiving FOLFOX adjuvant chemotherapy according to ERCC1-118 (rs11615, c.354T>C) (A), 
XRCC1-399 (rs25487, c.1196G>A) (B) and GSTP1-105 (rs1695, c.313A>G) (C) polymorphisms. Survival curves were estimated with the Kaplan–Meier 
method and compared using the log-rank test. 




GSTP1-105. For the 209 patients whose GSTP1 
genotype was defined, 48 (23%) had relapsed or died 
(20 with the A/A genotype, 22 with A/G, and 6 with 
G/G). The 3-year DFS rate was 79.4% (95% CI, 69.5 – 
86.3), 79.0% (95% CI, 68.8 – 86.3), and 70.0% (95% CI, 
45.1 – 85.3) in patients with A/A, A/G and G/G gen-
otypes, respectively (log-rank test, p=0.67) (Fig. 1C). 
 
Table 2. Univariate analyses between covariates of interest and dis-
ease-free survival. 
  n Events HR IC 95% p Har-
rell's 
Age       0.51 
< 65 years 101 22 1R     
≥ 65 years 109 26 1.17 [0.67 - 2.07] 0.58  
Sex      0.53 
Female 99 21 1R     
Male 111 27 1.25 [0.7 - 2.21] 0.45  
Tumor location      0.52 
Distal 143 32 1R     
Proximal 67 16 1.13 [0.62 - 2.05] 0.70  
Differentiation grade      0.55 
Well / Moderate 182 39 1R     
Poor 28 9 1.87 [0.91 - 3.87] 0.09  
Bowel perforation / 
obstruction 
     0.52 
Absent 194 44 1R     
Present 16 4 1.47 [0.53 - 4.1] 0.46  
Stage      0.58 
III A / III B (Tx, N1) 131 23 1R     
III C (Tx, N2) 79 25 2.03 [1.15 - 3.57] 0.01  
Lymph node ratio       0.60 
< 0.100 102 16 1R     
≥ 0.100 108 32 2.21 [1.21 - 4.03] 0.01  
MMR status      0.53 
dMMR 17 1 1R     
pMMR 193 47 4.11 [0.57 -29.76] 0.16  
ERCC1-118 (rs11615)      0.59 
C/C 49 6 1R     
C/T 88 24 2.48 [1.02 - 6.08] 0.14  
T/T 65 15 2.04 [0.79 - 5.25]  
XRCC1-399 (rs25487)      0.56 
G/G 94 22 1R     
G/A 80 15 0.81 [0.42 - 1.57] 0.33  
A/A 33 11 1.47 [0.71 - 3.04]  
GSTP1-105 (rs1695)      0.53 
A/A 97 20 1R     
A/G 92 22 1.21 [0.66 - 2.22] 0.67  
G/G 20 6 1.46 [0.59 - 3.64]  
Abbreviations: R, reference; ERCC1, Excision repair cross-complementing group 1; 
XRCC1, X-ray repair cross-complementing group 1; GSTP1, glutathione-S-transferase P1; 
dMMR, defective DNA Mismatch Repair; pMMR, proficient DNA Mismatch Repair. The 
cut-off value of LNR between metastatic and examined lymph nodes correponded to the 
median.  
 
Univariate and multivariate analyses of DFS 
In univariate analysis, tumor stage (stage IIIC vs 
IIIA/B: HR=2.03; p=0.01), LNR (≥ 0.100 vs< 0.100: 
HR=2.21; p=0.01) and differentiation grade (poor vs 
well/moderate: HR=1.87; p=0.09) were potentially 
associated with improved DFS (threshold, 10 %) (Ta-
ble 2). The genotype distribution of ERCC1-118, 
XRCC1-399 and GSTP1-105 polymorphisms did not 
show any significant correlation with DFS (Table 2). 
When grouping the heterozygous subjects with the 
homozygous genotype whose behavior was closest, 
we observed a trend toward improvement in DFS for 
ERCC1-118 (C/T + T/T vs C/C: HR=2.29; p=0.06), 
and for XRCC1-399 (A/A vs G/G + G/A: HR=1.61; 
p=0.16) (Table 3). With regard to GSTP1-105 poly-
morphism, no tendency could be ascribed for the 
heterozygous group; yet, pooling the A/G patients 
with the G/G or with the A/A group did not unravel 
any influence of GSTP1-105 polymorphism on DFS 
(data not shown).  
ERCC1-118 [C/C] and XRCC1-339 [G/G + G/A] 
were identified as favorable genotypes, whereas 
ERCC1-118 [C/T + T/T] and XRCC1-339 [A/A] rep-
resented unfavorable genotypes. In univariate analy-
sis, patients with at least one favorable genotype had 
a significantly longer DFS compared to patients with 
no favorable genotype (0 vs ≥ 1 favorable genotype: 
HR=2.42; p=0.02) (Table 3; Fig. 2).  
Multivariate analyses included all variables as-
sociated with DFS and having a p value ≤ 0.10 in the 
univariate analysis, i.e. tumor stage, LNR, differentia-
tion grade, and the combination of ERCC1-118 and 
XRCC1-339 polymorphisms because of the significant 
interaction between ERCC1-118 and XRCC1-399 
(p < 0.05). Multivariate analysis showed that none of 
these four variables was significantly associated with 
DFS (Table 4). Nevertheless, the combination of 
ERCC1-118 and XRCC1-399 polymorphisms was the 
variable associated with the lowest p value slightly 
above the threshold for statistical significance (0 vs ≥ 1 
favorable genotype: HR=2.03; p=0.06) (Table 4). 
 
 
Figure 2. DFS of stage III colon cancer patients receiving 
FOLFOX according to combined ERCC1/XRCC1 polymorphisms. 
Disease-free survival curves of stage III colon cancer patients receiving 
FOLFOX adjuvant chemotherapy according to the combination of 
ERCC1-118 (rs11615, c.354T>C) and XRCC1-399 (rs25487, c.1196G>A) 
polymorphisms. Survival curves were estimated with the Kaplan–Meier 
method and compared using the log-rank test. 




Table 3. Univariate analyses between ERCC1-118 and XRCC1-339 polymorphisms, separately or in combination, with disease-free survival. 
  n Events HR IC 95% P Harrell's 
ERCC1-118 (rs11615)      0.57 
C/C  49 6 1R     
C/T + T/T 153 39 2.29 [0.97 - 5.41] 0.06  
XRCC1-399 (rs25487)      0.54 
G/G + G/A 174 37 1R     
A/A  33 11 1.61 [0.82 - 3.12] 0.16  
ERCC1-118 (rs11615) AND XRCC1-339 (rs25487)      0.56 
≥ 1 genotype favorable: [ERCC1 C/C] AND/OR [XRCC1 G/G + G/A] 179 36 1R     
0 genotype favorable: [ERCC1 C/T + T/T] AND [XRCC1 A/A] 21 9 2.42 [1.16 - 5.03] 0.02  
Abbreviations: R, reference; ERCC1, Excision repair cross-complementing group 1; XRCC1, X-ray repair cross-complementing group 1. 
 
Table 4. Prognostic factors for disease-free survival in multivariate analysis. 
  n Events HR IC 95% P 
Differentiation grade      
Well / Moderate 174 36 1R    
Poor 26 9 1.58 [0.74 - 3.40] 0.24 
Stage      
III A / III B (Tx, N1) 127 23 1R    
III C (Tx, N2) 73 22 1.28 [0.62 - 2.64] 0.51 
Lymph node ratio      
< 0.100 102 16 1R    
≥ 0.100 98 29 1.62 [0.74 - 3.56] 0.23 
ERCC1-118 (rs11615) AND XRCC1-399 (rs25487)      
≥ 1 genotype favorable: [ERCC1 C/C] AND/OR [XRCC1 G/G + G/A] 179 36 1R    
0 genotype favorable: [ERCC1 C/T + T/T] AND [XRCC1 A/A] 21 9 2.03 [0.96 - 4.28] 0.06 
Abbreviations: R, reference; ERCC1, Excision repair cross-complementing group 1; XRCC1, X-ray repair cross-complementing group 1. The cut-off value of LNR between metastatic and examined 
lymph nodes corresponded to the median. 
A multivariate Cox model was constructed according to the "one variable for 10 events" rule. The discriminatory capacity was tested using the Harrell’s concordance index. Harrell’s C 
statistic was used to estimate the proportion of correct predictions. Harrell’s C index ranges from 0.5 (no discrimination) to 1 (perfect discrimination). 
Ten patients were excluded from the multivariate model because they had at least one missing polymorphism data (Harrell's C=0.65). 
 
Discussion 
The present study indicates that pharmaco-
genetic profiling of genes involved in DNA repair 
may influence clinical outcome of patients receiving 
FOLFOX adjuvant treatment for stage III colon cancer. 
This study focused on ERCC1-118, XRCC1-399 and 
GSTP1-105 genes polymorphisms because previously 
published data suggested a potential association be-
tween their SNPs and clinical outcome of patient 
treated with oxaliplatin-based chemotherapy for ad-
vanced CRC (7-12, 17). In our study, patients with no 
favorable genotype among ERCC1-118 and 
XRCC1-399 combination polymorphism have a 
shorter DFS upon FOLFOX adjuvant chemotherapy. 
However, the prognostic effect of this combined gen-
otype analysis did not reach statistical significance in 
multivariate analysis, possibly because the number of 
patients in our series was not large enough, notably 
for the group of patients having no favorable geno-
type. Nevertheless, regarding the association with 
DFS in multivariate analysis, the p value obtained 
when combining ERCC1 and XRCC1 genotypes was 
lower than for the other well-recognized prognostic 
factors (differentiation grade, LNR or tumor stage). A 
second possible explanation is that the polymorphism 
might be in linkage disequilibrium with another fac-
tor influencing survival to platinum-based chemo-
therapy within the same gene or in a gene nearby, 
such as ERCC2, as previously suggested (11). 
Several studies reported that SNP in ERCC1 
could predict the clinical outcome for patients re-
ceiving platinum-based chemotherapy for treatment 
of various tumors, including colorectal, gastric or lung 
cancers (19). Previous data suggested that T allele 
compared to C allele at codon 118 of ERCC1 gene, 
both coding for asparagine, was associated with 
higher ERCC1 mRNA level resulting in resistance to 
platinum drugs (20). DFS benefit for colon cancer pa-
tients with ERCC1-118 C/C in our study may support 
these findings. However, other analysis performed in 
ovarian cancer cells lines did not confirm these results 
(21), and the relationship between ERCC1-118 SNP 
and clinical outcome of patients receiving oxali-
platin-based chemotherapy for advanced CRC re-
mains controversial. Regarding patients with meta-
static colorectal cancer, several studies reported that 
ERCC1-118 C/C homozygote genotype was associ-
ated with better clinical outcome (7, 9, 11, 12, 22-25), 
whereas others showed no correlation between gen-




otype and survival (26, 27). In adjuvant setting, there 
is to date only one published study that evaluated the 
impact of ERCC1-118 SNP on survival of patients with 
stage III colon cancer (28). This retrospective study 
included 98 patients with stage III colon cancer re-
ceiving oxaliplatin-based (n = 53) or Mayo regimen 
(leucovorin and bolus fluorouracil) (n = 45) adjuvant 
chemotherapy. In univariate and multivariate surviv-
al analyses, ERCC1-118 polymorphism did not influ-
ence DFS, whatever the treatment administered (28). 
Several authors attempted to identify combina-
tion of genomic variants occurring in several genes 
involved in DNA repair or metabolism drugs that 
may help predicting efficacy of platinum-based 
chemotherapy for CRC patients (11, 12, 22). Liang et al 
evaluated the prognostic value of ERCC1-118 and 
XRCC1-399 SNP, separately and in combination, in 
113 patients receiving oxaliplatin-based chemothera-
py for metastatic CRC (26). This retrospective study 
reported that the favorable genotypes of ERCC1-118 
and XRCC1-399 polymorphisms, in combination but 
not individually, were an independent prognostic 
factor for disease control rate and overall survival 
(26). However while favorable genotypes for 
ERCC1-118 SNP were identical in both studies (C/C 
homozygous), the XRCC1-399 favorable genotype 
(A/A homozygous) differed from ours (G/G + G/A) 
(26). 
The first study evaluating the value of 
XRCC1-399 as a pharmacogenetic marker was per-
formed in 61 patients with advanced CRC receiving 
5FU/oxaliplatin chemotherapy (8). The authors 
showed that 73% (8/11) of responders had a G/G 
genotype and 27% (3/11) were G/A, while 66% 
(33/50) of non-responders showed A/A or G/A gen-
otypes (p=0.038) (8). Patients carrying at least one A 
allele were at a 5.2 fold increased risk to be resistant to 
oxaliplatin-based chemotherapy (8). More recently, 
another study reported similar results in 62 patients 
treated with oxaliplatin-based chemotherapy for 
metastatic CRC (9). In keeping, we observed in our 
study that DFS of patients with XRCC1-399 A/A 
genotype was shorter. However, other studies in-
cluding between 61 and 166 patients failed to detect a 
significant prognostic impact of XRCC1-399 SNP in 
metastatic setting (11, 22, 24, 29). This indicates that 
XRCC1 genotype is probably not strongly associated 
with clinical outcome, though subtle differences have 
been reported in some studies.  
GSTP1 is a member of a superfamily of metabolic 
enzymes involved in the detoxification of platinum 
compounds. Stoehlmacher et al have reported in two 
studies that GSTP1-105 G allele coding a Valine was 
associated with increased survival of patients with 
advanced CRC receiving 5-FU/oxaliplatin chemo-
therapy (10, 11). More recently, Chen et al confirmed 
these results in a series of Asian metastatic CRC pa-
tients, with higher tumor response and longer sur-
vival seen in the group of patients with at least one 
GSTP1-105 G allele (12). However, the association 
between GSTP1-105 polymorphism and efficacy in the 
context of oxaliplatin-based treatment remains con-
troversial. Indeed, some studies did not confirm the 
prognostic value of GSTP1-105 SNP in metastatic (22, 
25) or adjuvant (28) oxaliplatin-based treatment.  
In conclusion, this study suggests that phar-
macogenetic profiling of genes involved in DNA re-
pair may have an impact on clinical outcome of pa-
tients receiving FOLFOX adjuvant treatment for 
stage III colon cancer. In univariate analysis, combi-
nation of ERCC1-118 and XRCC1-399 emerged as 
promising prognostic markers for DFS, although this 
combined genotype factor did not reach statistical 
significance in multivariate analysis. Future prospec-
tive studies with large sample sizes are required to 
confirm and extend our findings. 
Acknowledgments  
We thank Thomas Le Picard for his technical 
help. The authors thank all their colleagues who 
helped them for data collection.  
Funding 
Claire Goumard was a recipient of a grant of 
«Institut National du Cancer» (INCa). The funding 
source had no role in study design, data collection, 
data analysis, data interpretation or the writing of the 
report. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of 
preclinical and clinical studies. Ann Oncol 1998;9:1053-71. 
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. 
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment 
in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47. 
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. 
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon 
cancer. N Engl J Med 2004;350:2343-51. 
4. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G et 
al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as 
surgical adjuvant chemotherapy for stage II and III colon cancer: results from 
NSABP C-07. J Clin Oncol 2007;25:2198-204. 
5. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of 
cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11. 
6. Zaanan A, Meunier K, Sangar F, Flejou JF, Praz F. Microsatellite instability in 
colorectal cancer: from molecular oncogenic mechanisms to clinical 
implications. Cell Oncol (Dordr) 2011;34:155-76. 
7. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ et al. ERCC1 
and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based 
chemotherapies in gastric and colorectal cancer: a systemic review and 
meta-analysis. Clin Cancer Res 2011;17:1632-40. 
8. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D et al. A 
polymorphism of the XRCC1 gene predicts for response to platinum based 
treatment in advanced colorectal cancer. Anticancer Res 2001;21:3075-9. 




9. Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang H et al. Genetic polymorphism of 
XRCC1 correlated with response to oxaliplatin-based chemotherapy in 
advanced colorectal cancer. Pathol Oncol Res 2012;18:1009-14. 
10. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC et al. 
Association between glutathione S-transferase P1, T1, and M1 genetic 
polymorphism and survival of patients with metastatic colorectal cancer. J 
Natl Cancer Inst 2002;94:936-42. 
11. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S et al. A 
multivariate analysis of genomic polymorphisms: prediction of clinical 
outcome to 5-FU/oxaliplatin combination chemotherapy in refractory 
colorectal cancer. Br J Cancer 2004;91:344-54. 
12. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS et al. Influence of 
GSTP1 I105V polymorphism on cumulative neuropathy and outcome of 
FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 
2010;101:530-5. 
13. McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel 
therapeutic target to overcome chemoresistance in cancer therapy. Nucleic 
Acids Res 2012;40:9990-10004. 
14. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. 
XRCC1 and DNA polymerase beta in cellular protection against cytotoxic 
DNA single-strand breaks. Cell Res 2008;18:48-63. 
15. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S et al. 
Transfection of glutathione S-transferase (GST)-pi antisense complementary 
DNA increases the sensitivity of a colon cancer cell line to adriamycin, 
cisplatin, melphalan, and etoposide. Cancer Res 1996;56:3577-82. 
16. de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M. A review of 
GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous 
infusion in advanced colorectal cancer: evolution of a regimen. Groupe 
d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). 
Eur J Cancer 1998;34:619-26. 
17. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC et al. 
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response 
to oxaliplatin/5-fluorouracil combination chemotherapy in patients with 
advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7. 
18. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A 
et al. Impact of p53 expression and microsatellite instability on stage III colon 
cancer disease-free survival in patients treated by 5-fluorouracil and 
leucovorin with or without oxaliplatin. Ann Oncol 2010;21:772-80. 
19. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in 
DNA repair and resistance to anticancer drugs. Anticancer Res 
2010;30:3223-32. 
20. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J et al. ERCC1 
gene polymorphism as a predictor for clinical outcome in advanced colorectal 
cancer patients treated with platinum-based chemotherapy. Clin Adv 
Hematol Oncol 2003;1:162-6. 
21. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F et al. Comparison 
of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are 
equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J 
Oncol 2000;16:555-60. 
22. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al. 
Pharmacogenetic profiling in patients with advanced colorectal cancer treated 
with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54. 
23. Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Diaz-Rubio E et 
al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be 
combined with oxaliplatin as first-line chemotherapy in advanced colorectal 
cancer. Eur J Cancer 2008;44:1229-37. 
24. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J et al. 
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer 
patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J 
Cancer 2008;99:1050-5. 
25. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M et al. 
Pharmacogenetic assessment of toxicity and outcome in patients with 
metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: 
FFCD 2000-05. J Clin Oncol 2010;28:2556-64. 
26. Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW. The combination of ERCC1 
and XRCC1 gene polymorphisms better predicts clinical outcome to 
oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer 
Chemother Pharmacol 2010;66:493-500. 
27. Spindler KL, Andersen RF, Jensen LH, Ploen J, Jakobsen A. EGF61A>G 
polymorphism as predictive marker of clinical outcome to first-line 
capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol 
2010;21:535-9. 
28. Farina Sarasqueta A, van Lijnschoten G, Lemmens VE, Rutten HJ, van den 
Brule AJ. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon 
carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and 
ERCC2 good predictive markers? Mol Diagn Ther 2011;15:277-83. 
29. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P et al. 
Molecular markers of response and toxicity to FOLFOX chemotherapy in 
metastatic colorectal cancer. Br J Cancer 2009;101:998-1004. 
